Literature DB >> 15156289

[Botulinum toxin in otorhinolaryngology].

S Rohrbach1, R Laskawi.   

Abstract

BACKGROUND AND OBJECTIVES: Through its anticholinergic effect, botulinum toxin is a suitable therapeutic option for dysfunctions of the muscular and the autonomic nervous system. PATIENTS/
METHODS: Beside the classical indications like facial hyperkinesis (i.e. blepharospasm, hemifacial spasm), the treatment of complex dystonias (oromandibular dystonia, spasmodic dystonia, cervical dystonia), gustatory sweating, hypersalivation and crocodile tears is successful. Botulinum toxin is an alternative treatment of tension type headache and migraine. A new indication of botulinum toxin application may involve the treatment of nasal hypersecretion through the effect on the nasal glands.
RESULTS: The positive therapeutic effect starts a few days after treatment and lasts longer in disorders of the autonomic nervous system. Because of its temporally limited therapeutic effect, the patients need further treatment. Side-effects are rare.
CONCLUSIONS: Botulinum toxin is an effective treatment for a variety disorders with different etiologies and has very few side effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156289     DOI: 10.1007/s00106-004-1098-9

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  14 in total

Review 1.  Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system.

Authors:  M Naumann; W H Jost; K V Toyka
Journal:  Arch Neurol       Date:  1999-08

Review 2.  Idiopathic cervical dystonia: an overview.

Authors:  M Stacy
Journal:  Neurology       Date:  2000       Impact factor: 9.910

3.  Minimally invasive application of botulinum toxin type A in nasal hypersecretion.

Authors:  S Rohrbach; R Laskawi
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2001 Nov-Dec       Impact factor: 1.538

4.  Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs.

Authors:  S Rohrbach; A Olthoff; R Laskawi; B Giefer; W Götz
Journal:  Ann Otol Rhinol Laryngol       Date:  2001-11       Impact factor: 1.547

Review 5.  Frey's syndrome. Treatment with botulinum toxin.

Authors:  Rainer Laskawi; Saskia Rohrbach
Journal:  Curr Probl Dermatol       Date:  2002

6.  Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands.

Authors:  Maik Ellies; Rainer Laskawi; Saskia Rohrbach-Volland; Christian Arglebe; Wolfgang Beuche
Journal:  Laryngoscope       Date:  2002-01       Impact factor: 3.325

7.  Neuronal nitric oxide synthase-immunoreactivity. A neuromodulating system independent of peripheral nasal gland denervation in guinea pig nasal mucosal tissue after treatment with botulinum toxin type A.

Authors:  Saskia Rohrbach; Arno Olthoff; Rainer Laskawi; Werner Götz
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2002 Sep-Oct       Impact factor: 1.538

8.  [Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin].

Authors:  R Laskawi; S Rohrbach
Journal:  Laryngorhinootologie       Date:  2001-12       Impact factor: 1.057

9.  Rhinorrhea is decreased in dogs after nasal application of botulinum toxin.

Authors:  C M Shaari; I Sanders; B L Wu; H F Biller
Journal:  Otolaryngol Head Neck Surg       Date:  1995-04       Impact factor: 3.497

10.  The effect of botulinum toxin type A injection for intrinsic rhinitis.

Authors:  K S Kim; S S Kim; J H Yoon; J W Han
Journal:  J Laryngol Otol       Date:  1998-03       Impact factor: 1.469

View more
  8 in total

1.  [Use of botulinum toxin in ORL departments in Germany].

Authors:  P Matthes; J Kruegel; C Karapantzou; J Winterhoff; R Laskawi
Journal:  HNO       Date:  2010-05       Impact factor: 1.284

2.  [On the diagnosis and treatment of parotid gland tumors. Results of a nationwide survey of ENT hospitals in Germany].

Authors:  S F Preuss; O Guntinas-Lichius
Journal:  HNO       Date:  2006-11       Impact factor: 1.284

Review 3.  [Botulinum toxin treatment in the head and neck region: current aspects, developments, and problems].

Authors:  R Laskawi
Journal:  HNO       Date:  2007-06       Impact factor: 1.284

Review 4.  Hypersalivation: update of the German S2k guideline (AWMF) in short form.

Authors:  Armin Steffen; Wolfgang Jost; Tobias Bäumer; Dirk Beutner; Sabine Degenkolb-Weyers; Martin Groß; Maria Grosheva; Samer Hakim; Kai G Kahl; Rainer Laskawi; Rebekka Lencer; Jan Löhler; Thekla Meyners; Saskia Rohrbach-Volland; Rainer Schönweiler; Sara-Christina Schröder; Sebastian Schröder; Heidrun Schröter-Morasch; Maria Schuster; Susanne Steinlechner; Roland Urban; Orlando Guntinas-Lichius
Journal:  J Neural Transm (Vienna)       Date:  2019-04-10       Impact factor: 3.575

Review 5.  [Treatment of laryngeal movement disorders with botulinum toxins: part 1: History and mode of action].

Authors:  C Schwemmle; M Ptok
Journal:  HNO       Date:  2007-05       Impact factor: 1.284

6.  [Botulinum toxin A as a treatment of traumatic salivary gland fistulas].

Authors:  T Breuer; A Ferrazzini; R Grossenbacher
Journal:  HNO       Date:  2006-05       Impact factor: 1.284

7.  Surgical and conservative methods for restoring impaired motor function - facial nerve, spinal accessory nerve, hypoglossal nerve (not including vagal nerve or swallowing).

Authors:  R Laskawi; S Rohrbach
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 8.  The use of botulinum toxin in head and face medicine: an interdisciplinary field.

Authors:  Rainer Laskawi
Journal:  Head Face Med       Date:  2008-03-10       Impact factor: 2.151

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.